

On-line Table 1: Differences in NAA/Cr ratios among 3 observed groups and correlations with CPE scores and current CD4+ counts

ANOVA NAA/Cr	No.	Mean	SD	F	P	Correlation with CPE ^a and CD4 Counts ^b ρ (P)
FSWM (right)						
cART	31	1.683	0.362	14.956	<.001 ^c	−0.208 (.26) ^a
Naïve chr. HIV	19	1.670	0.325			−0.033 (.83) ^b
Control	41	2.041	0.269			
Ventral ACG (right)						
cART	31	1.347	0.221	12.434	<.001 ^c	0.064 (.73) ^a
Naïve chr. HIV	19	1.420	0.305			−0.230 (.11) ^b
Control	41	1.604	0.178			
Ventral ACG (left)						
cART	31	2.163	0.350	7.481	.001 ^c	−0.156 (.40) ^a
Naïve chr. HIV	19	2.127	0.335			0.002 (.99) ^b
Control	41	2.420	0.320			
FSWM (left)						
cART	31	1.597	0.183	10.616	<.001 ^c	−0.009 (.96) ^a
Naïve chr. HIV	19	1.530	0.181			0.013 (.93) ^b
Control	41	1.749	0.197			
FDWM (right)						
cART	31	2.441	0.462	10.786	<.001 ^c	0.084 (.65) ^a
Naïve chr. HIV	19	2.249	0.404			0.345 (.016) ^{b,c}
Control	41	2.726	0.324			
Dorsal ACG (right)						
cART	31	1.956	0.283	5.496	.006 ^c	0.181 (.33) ^a
Naïve chr. HIV	19	1.846	0.273			0.137 (.35) ^b
Control	41	2.082	0.247			
Dorsal ACG (left)						
cART	31	1.551	0.300	14.308	<.001 ^c	−0.086 (.64) ^a
Naïve chr. HIV	19	1.592	0.543			−0.045 (.76) ^b
Control	41	1.995	0.347			
FDWM (left)						
cART	31	1.338	0.217	10.775	<.001 ^c	−0.056 (.76) ^a
Naïve chr. HIV	19	1.387	0.284			−0.200 (.17) ^b
Control	41	1.582	0.218			
PSWM (right)						
cART	31	1.975	0.349	6.937	.002 ^c	−0.194 (.30) ^a
Naïve chr. HIV	19	1.984	0.360			−0.094 (.53) ^b
Control	41	2.260	0.367			
PCG (right)						
cART	31	1.540	0.158	14.208	<.001 ^c	−0.138 (.46) ^a
Naïve chr. HIV	19	1.479	0.157			0.100 (.50) ^b
Control	41	1.742	0.250			
PCG (left)						
cART	31	2.089	0.394	12.535	<.001 ^c	0.023 (.90) ^a
Naïve chr. HIV	19	2.052	0.427			−0.044 (.76) ^b
Control	41	2.507	0.414			
PSWM (left)						
cART	31	1.942	0.226	8.063	.001 ^c	−0.030 (.87) ^a
Naïve chr. HIV	19	1.705	0.219			0.411 (.004) ^{b,c}
Control	41	1.998	0.308			

Note:—chr. indicates chronic.

^a CPE score.

^b CD4+ count.

^c Significant.

On-line Table 2: Post hoc analysis using the Tukey honest significant difference test among 3 groups of patients, according to voxel localizations^a

Tukey Test	HIV+ on Therapy vs HIV+ Therapy-Naïve	HIV+ Therapy-Naïve vs Controls	HIV+ on Therapy vs Controls
FSWM (right)			
NAA/Cr	.99	<.001 ^b	<.001 ^b
Cho/Cr	.93	.084	.31
mIns/Cr	.96	.16	.17
Ventral ACG (right)			
NAA/Cr	.50	<.001 ^b	.011 ^b
Cho/Cr	.10	.79	.25
mIns/Cr	.53	.002 ^b	.14
Ventral ACG (left)			
NAA/Cr	.93	.005 ^b	.006 ^b
Cho/Cr	.99	.55	.54
mIns/Cr	.24	.83	.076
FSWM (left)			
NAA/Cr	.44	.003 ^b	<.001 ^b
Cho/Cr	.72	<.001 ^b	.032 ^b
mIns/Cr	.47	.98	.34
FDWM (right)			
NAA/Cr	.22	.008 ^b	<.001 ^b
Cho/Cr	.57	.19	.89
mIns/Cr	.96	.97	.89
Dorsal ACG (right)			
NAA/Cr	.33	.023 ^b	.005 ^b
Cho/Cr	.50	.033 ^b	.58
mIns/Cr	.86	.74	.99
Dorsal ACG (left)			
NAA/Cr	.93	<.001 ^b	.001 ^b
Cho/Cr	.78	.23	.09
mIns/Cr	.07	<.001 ^b	.012 ^b
FDWM (left)			
NAA/Cr	.75	<.001 ^b	.009 ^b
Cho/Cr	.35	.68	.08
mIns/Cr	.34	.001 ^b	.24
PSWM (right)			
NAA/Cr	.99	.004 ^b	.018 ^b
Cho/Cr	.99	.70	.84
mIns/Cr	.99	.06	.10
PCG (right)			
NAA/Cr	.56	<.001 ^b	<.001 ^b
Cho/Cr	.13	<.001 ^b	.80
mIns/Cr	.75	.99	.78
PCG (left)			
NAA/Cr	.95	<.001 ^b	<.001 ^b
Cho/Cr	.63	.023 ^b	.38
mIns/Cr	.51	.96	.34
PSWM (left)			
NAA/Cr	.65	.008 ^b	<.001 ^b
Cho/Cr	.92	.021 ^b	.020 ^b
mIns/Cr	.66	.99	.59

^a Data are *P* values.

^b Significant.

On-line Table 3: Differences in Cho/Cr ratios among 3 observed groups and correlations with CPE score and current CD4+ count

ANOVA Cho/Cr	No.	Mean	SD	F	P	Correlation with CPE ^a and CD4 Counts ^b ρ (P)
FSWM (right)						
cART	31	1.078	0.249	2.588	.08	0.037 (.84) ^a
Naïve chr. HIV	19	1.055	0.212			0.034 (.82) ^b
Control	41	0.971	0.170			
Ventral ACG (right)						
cART	31	1.103	0.152	2.204	.12	0.494 (.005) ^{a,c}
Naïve chr. HIV	19	1.191	0.198			−0.298 (.040) ^{b,c}
Control	41	1.126	0.107			
Ventral ACG (left)						
cART	31	1.031	0.142	0.812	.45	−0.084 (.65) ^a
Naïve chr. HIV	19	1.039	0.181			0.071 (.63) ^b
Control	41	0.984	0.215			
FSWM (left)						
cART	31	1.032	0.115	8.466	<.001 ^c	0.209 (.26) ^a
Naïve chr. HIV	19	1.061	0.134			−0.163 (.27) ^b
Control	41	1.152	0.135			
FDWM (right)						
cART	31	0.876	0.173	1.569	.21	0.230 (.21) ^a
Naïve chr. HIV	19	0.824	0.156			0.126 (.39) ^b
Control	41	0.802	0.186			
Dorsal ACG (right)						
cART	31	0.789	0.143	3.247	.044 ^c	0.557 (.001) ^{a,c}
Naïve chr. HIV	19	0.828	0.110			−0.155 (.29) ^b
Control	41	0.862	0.104			
Dorsal ACG (left)						
cART	31	1.039	0.137	2.683	.07	0.259 (.16) ^a
Naïve chr. HIV	19	1.075	0.229			−0.095 (.52) ^b
Control	41	0.965	0.198			
FDWM (left)						
cART	31	1.138	0.183	2.395	.10	0.386 (.032) ^{a,c}
Naïve chr. HIV	19	1.202	0.195			−0.201 (.17) ^b
Control	41	1.106	0.113			
PSWM (right)						
cART	31	1.059	0.132	0.365	.69	−0.176 (.34) ^a
Naïve chr. HIV	19	1.053	0.201			0.091 (.54) ^b
Control	41	1.025	0.193			
PCG (right)						
cART	31	1.015	0.121	9.568	<.001 ^c	0.202 (.28) ^a
Naïve chr. HIV	19	1.085	0.140			−0.240 (.10) ^b
Control	41	1.143	0.117			
PCG (left)						
cART	31	0.843	0.243	3.694	.029 ^c	0.129 (.49) ^a
Naïve chr. HIV	19	0.899	0.212			−0.194 (.19) ^b
Control	41	0.978	0.185			
PSWM (left)						
cART	31	0.808	0.147	5.441	.006 ^c	0.255 (.167) ^a
Naïve chr. HIV	19	0.795	0.113			0.111 (.45) ^b
Control	41	0.886	0.099			

Note:—chr. indicates chronic.

^a CPE score.

^b CD4+ count.

^c Significant.

On-line Table 4: Differences in mlns/Cr ratios among 3 observed groups and correlations with CPE score and current CD4+ count

ANOVA mlns/Cr	No.	Mean	SD	F	P	Correlation with CPE ^a and CD4 Counts ^b ρ (P)
FSWM (right)						
cART	31	0.489	0.159	2.448	.10	−0.019 (.92) ^a
Naïve chr. HIV	19	0.499	0.166			−0.010 (.94) ^b
Control	41	0.424	0.129			
Ventral ACG (right)						
cART	31	0.685	0.214	6.426	.002 ^c	0.150 (.42) ^a
Naïve chr. HIV	19	0.630	0.197			0.184 (.21) ^b
Control	41	0.538	0.125			
Ventral ACG (left)						
cART	31	0.466	0.164	2.462	.09	−0.191 (.29) ^a
Naïve chr. HIV	19	0.532	0.153			−0.254 (.08) ^b
Control	41	0.446	0.113			
FSWM (left)						
cART	31	0.586	0.150	1.052	.35	0.096 (.61) ^a
Naïve chr. HIV	19	0.636	0.157			−0.219 (.13) ^b
Control	41	0.579	0.141			
FDWM (right)						
cART	31	0.391	0.139	0.110	.90	−0.079 (.67) ^a
Naïve chr. HIV	19	0.402	0.206			−0.069 (.64) ^b
Control	41	0.383	0.127			
Dorsal ACG (right)						
cART	31	0.382	0.125	0.288	.75	0.046 (.89) ^a
Naïve chr. HIV	19	0.399	0.103			−0.098 (.51) ^b
Control	41	0.402	0.115			
Dorsal ACG (left)						
cART	31	0.780	0.210	1.933	<.001 ^c	−0.024 (.89) ^a
Naïve chr. HIV	19	0.658	0.185			0.317 (.028) ^{b,c}
Control	41	0.506	0.168			
FDWM (left)						
cART	31	0.691	0.199	6.549	.002 ^c	0.187 (.31) ^a
Naïve chr. HIV	19	0.617	0.207			0.144 (.33) ^b
Control	41	0.537	0.147			
PSWM (right)						
cART	31	0.726	0.178	3.503	.034 ^c	0.097 (.60) ^a
Naïve chr. HIV	19	0.732	0.206			−0.013 (.93) ^b
Control	41	0.627	0.170			
PCG (right)						
cART	31	0.602	0.121	0.298	.74	0.230 (.21) ^a
Naïve chr. HIV	19	0.632	0.119			−0.201 (.17) ^b
Control	41	0.605	0.167			
PCG (left)						
cART	31	0.471	0.184	1.037	.36	−0.187 (.31) ^a
Naïve chr. HIV	19	0.528	0.216			−0.135 (.36) ^b
Control	41	0.459	0.149			
PSWM (left)						
cART	31	0.402	0.109	0.529	.59	0.19 (.31) ^a
Naïve chr. HIV	19	0.430	0.108			−0.156 (.29) ^b
Control	41	0.400	0.114			

Note:—chr. indicates chronic.

^a CPE score.

^b CD4+ count.

^c Significant.